Prioritizing Genes Linked to Parkinson's Disease
Author Information
Author(s): Lara M. Lange, Catalina Cerquera-Cleves, Marijn Schipper, Georgia Panagiotaropoulou, Alice Braun, Julia Kraft, Swapnil Awasthi, Nathaniel Bell, Danielle Posthuma, Stephan Ripke, Cornelis Blauwendraat, Karl Heilbron
Primary Institution: Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
Hypothesis
The study aims to prioritize genes underlying Parkinson's disease genome-wide association study (GWAS) signals.
Conclusion
The study identified 46 high-confidence genes that may serve as potential therapeutic targets for Parkinson's disease.
Supporting Evidence
- Drugs supported by genetic evidence are more likely to be approved.
- Identified 120 independent associations with significant p-values.
- Prioritized genes include well-established PD genes and novel candidates.
- Many prioritized genes hold potential for drug repurposing or new therapeutic developments.
Takeaway
Researchers found important genes that could help develop new treatments for Parkinson's disease by looking at genetic data.
Methodology
The study used a polygenic priority score (PoPS) method to analyze data from the largest published PD GWAS in East Asian and European ancestries.
Limitations
The study could not assess genes on chromosome X and may not generalize across diverse genetic populations.
Participant Demographics
The study included individuals of East Asian and European ancestries.
Statistical Information
P-Value
p<5×10−8
Statistical Significance
p<5×10−8
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website